Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Dual-Action p38α Inhibitors Accelerate Dephosphorylation Dyn
2026-05-21
This study reveals that certain kinase inhibitors, including those targeting p38α MAP kinase, can act dually by both inhibiting kinase activity and facilitating phosphatase-driven dephosphorylation. These findings introduce a structurally-informed strategy for enhancing the specificity and potency of kinase-targeted therapies, with broad implications for inflammation and vascular research.
CUDC-907: Technical Protocols for Dual PI3K and HDAC Inhibit
2026-05-20
CUDC-907 provides researchers with a dual PI3K and HDAC inhibitor optimized for in vitro studies of cell signaling, cell cycle regulation, and apoptosis in cancer models. It is not suitable for diagnostic or clinical use and should be applied strictly within validated laboratory workflows.
IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in TNBC
2026-05-20
This study reveals that the m6A reader IGF2BP3 stabilizes FZD1/7 transcripts, activating β-catenin signaling and promoting stem-like features and carboplatin resistance in triple-negative breast cancer (TNBC). Pharmacological inhibition of FZD1/7 sensitizes cancer stem-like cells to carboplatin, suggesting a promising strategy to overcome chemoresistance and improve TNBC therapy.
U0126 in Neurodegeneration: Precision MEK1/2 Inhibition for
2026-05-19
Explore how U0126, a selective MEK1/2 inhibitor, uniquely empowers neurodegeneration research by dissecting MAPK/ERK pathway dynamics and tau pathology. This article delivers in-depth analysis, protocol guidance, and actionable insights beyond standard cancer or autophagy applications.
Erastin as a Ferroptosis Inducer: Protocols, Workflows, and
2026-05-19
Erastin from APExBIO is a precision ferroptosis inducer that unlocks reproducible, iron-dependent cell death assays, especially in RAS and BRAF mutant tumor cells. This guide distills protocol enhancements, advanced applications, and troubleshooting strategies to accelerate ferroptosis research and cancer biology workflows.
U0126-EtOH: Precision MEK1/2 Inhibition for Neuroprotection
2026-05-18
U0126-EtOH stands out as a potent, selective MEK1/2 inhibitor tailored for dissecting MAPK/ERK pathway function in models of neuroprotection and inflammation. This article details high-fidelity experimental workflows, actionable protocol enhancements, and troubleshooting strategies, empowering researchers to maximize data quality and reproducibility with APExBIO’s U0126-EtOH.
Tubastatin A Reduces Myocardial Damage via Pyroptosis and Ne
2026-05-18
The referenced study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, alleviates post-resuscitation myocardial injury in a porcine cardiac arrest model by suppressing GSDME-mediated pyroptosis and MLKL-mediated necroptosis. These findings highlight a targeted epigenetic approach to mitigating programmed cell death after ischemia-reperfusion insult, with translational potential for cardiac protection.
Etoposide (VP-16): Applied Workflows for DNA Damage Assays
2026-05-17
Etoposide (VP-16) enables precise DNA double-strand break induction, empowering researchers to dissect apoptosis and DNA repair mechanisms across cancer models. Discover stepwise protocols, troubleshooting strategies, and innovative use-cases that set APExBIO’s etoposide apart for cancer chemotherapy research and genome integrity studies.
AT13387: Precision Hsp90 Inhibition for Apoptosis Pathways
2026-05-16
Explore how AT13387, a potent Hsp90 inhibitor, enables advanced cancer biology research by dissecting apoptosis and cell cycle arrest mechanisms. This article provides a unique assay-focused perspective, integrating recent discoveries on regulated cell death and offering actionable guidance for experimental design.
EZ Cap™ mCherry mRNA: A Next-Gen Benchmark for Fluorescent R
2026-05-15
Explore the scientific basis for EZ Cap™ mCherry mRNA's unmatched stability and translational efficiency as a red fluorescent protein mRNA. This article uniquely examines the interplay of advanced capping, nucleotide modification, and excipient-augmented delivery—grounded in the latest nanoparticle loading research.
Nilotinib (AMN-107): Precision BCR-ABL Inhibitor for CML Res
2026-05-15
Nilotinib (AMN-107) is a highly selective, orally bioavailable tyrosine kinase inhibitor targeting BCR-ABL in chronic myeloid leukemia research. It demonstrates nanomolar potency against both wild-type and mutant forms, supporting robust kinase pathway interrogation. Its validated use in cell-based and in vivo models underpins its value in translational cancer studies.
Dual-Action Kinase Inhibitors Promote p38α Dephosphorylation
2026-05-14
This study reveals that certain kinase inhibitors can simultaneously inhibit kinase activity and accelerate p38α MAP kinase dephosphorylation by stabilizing an activation loop conformation accessible to phosphatases. These insights suggest new strategies for achieving higher specificity and potency in kinase-targeted research and drug development.
Norovirus Uses NINJ1 for Selective Viral Protein Secretion
2026-05-14
Song et al. (2025) reveal that murine norovirus co-opts the host membrane protein NINJ1 to enable selective secretion of its NS1 protein, distinguishing this mechanism from bulk DAMP release during programmed cell death. This discovery advances understanding of viral manipulation of host cell death pathways, with implications for antiviral and apoptosis research.
Cyclopamine: Applied Workflows for Hedgehog Signaling Inhibi
2026-05-13
Cyclopamine, a targeted Hedgehog signaling inhibitor from APExBIO, unlocks precise control of cancer and developmental pathways in both cell-based and animal models. This article outlines advanced use-cases, robust experimental workflows, and troubleshooting insights to help researchers maximize reproducibility and insight when interrogating Hh pathway function.
Tubastatin A: HDAC6 Inhibition for Translational Breakthroug
2026-05-13
This thought-leadership article explores Tubastatin A's unique mechanistic advantages as a selective HDAC6 inhibitor, reviews key preclinical evidence—including new findings on post-resuscitation myocardial protection—and offers strategic guidance for translational researchers. By bridging epigenetic modulation, precision cell death control, and disease-specific applications, the article distinguishes itself from standard product pages while providing actionable workflow advice. Anchored in recent cardiac injury models and supported by APExBIO product intelligence, it delivers a forward-looking perspective on HDAC6 inhibition in translational science.
7828 records 21/522 page Previous Next First page 上5页 2122232425 下5页 Last page